

09/27/01

JC886
U.S. PTO

04 - 28 - 01

PTO/SB/05 (2/98)
A
for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37C.F.R. §1.53(b))

Attorney Docket No.		PC9869B
First Named Inventor or Application Identifier		Anton Fliri
Title	SUBSTITUTED BICYCLIC DERIVATIVES FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS	
Express Mail Label No.	EL625565265US	

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)

2. Specification [Total Pages 82]
(preferred arrangement set forth below)

- Descriptive title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R&D
- Reference in Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

3. Drawing(s) (35 U.S.C. 11.3) [Total sheets]

4. Oath or Declaration [Total pages]

- a. Newly executed (original or copy)
- b. Copy from a prior application (37 CFR §1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
 - i. **DELETION OF INVENTOR(S)**
Signed statement attached deleting
inventor(s) named in the prior application,
see 37 C.F.R. §§1.63(d)(2) and 1.33(b).

5. Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ADDRESS TO:
Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

6. Microfiche Computer Program (Appendix)

7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

- a. Computer Readable Copy
- b. Paper Copy (identical to computer copy)
- c. Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. Assignment Papers (cover sheet & document(s))

9. 37 C.F.R. §3.73(b) Statement Power of Attorney
(when there is an assignee)

10. English Translation Document (if applicable)

11. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations

12. Preliminary Amendment

13. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)

14. *Small Entity Statement filed in prior application,
Statement(s) Status still proper and desired
(PTO/SB/09-12)

15. Certified Copy of Priority Document(s)
(if foreign priority is claimed)

16. Other: Priority Claim
U.S. Serial No. 60/083,421
filed April 29, 1998

**NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).*

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

Continuation Divisional Continuation-in-part (CIP) of prior application No: 09// 300,262

Prior application information: Examiner T. Solola Group/Art Unit: 1626**18. CORRESPONDENCE ADDRESS**

<input type="checkbox"/> Customer Number or Bar Code Label		(Insert Customer No. or Attach bar code label here)			<input type="checkbox"/> or <input checked="" type="checkbox"/> Correspondence address below
Name	Paul H. Ginsburg				
Address	Pfizer Inc				
Address	235 East 42nd Street, 20th Floor				
City	New York	State	New York	Zip Code	10017-5755
Country	United States Of America	Telephone	(212)573-2369	Fax	(212)573-1939
NAME (Print/type)	E. Victor Donahue			Registration No. (Attorney/Agent)	35,492
Signature	<u>E. V. D.</u>			Date	September 27 2001

FEE TRANSMITTAL

Patent fees are subject to annual revision on October 1.
These are the fees effective October 1, 1997.

Small Entity payments **must** be supported by a small entity statement, otherwise large entity fees must be paid. See Forms PTO/SB/09-12.

See 37 C.F.R. §§ 1.27 and 1.28.

Total Amount of Payment (\$710.00)

Complete if Known	
Application Number	Express Mail Label No. EL625565265US
Filing Date	September 27, 2001
First Named Inventor	Anton Fliri
Examiner Name	T. Solola (anticipated)
Group/Art Unit	1626 (anticipated)
Attorney Docket No.	PC9869B

METHOD OF PAYMENT (check one)

The commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number 16-1445

Deposit Account Name Pfizer Inc

Charge Any Additional Fee Required Under 37 C.F.R. §§ 1.16 and 1.17. Charge the Issue Fee Set in 37 C.F.R. § 1.18 at the Mailing of the Notice of Allowance.

2. Payment Enclosed:

Check Money Order Other

FEE CALCULATION (continued)

3. ADDITIONAL FEES		Fee Description				Fee Paid
Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Code	Fee (\$)	
		105	130	205	65	Surcharge – late fee or oath
		127	50	227	25	Surcharge—late provisional filing fee or cover sheet
		139	130	139	130	Non-English specification
		147	2,520	147	2,520	For filing a request for reexamination
		112	920*	112	920*	Requesting publication of SIR prior to Examiner action
		113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action
		115	110	215	55	Extension for reply within first month
		116	390	216	195	Extension for reply within second month
		117	890	217	445	Extension for reply within third month
		118	1,390	218	695	Extension for reply within fourth month
		128	1,890	228	945	Extension for reply within fifth month
		119	310	219	155	Notice of Appeal
		120	310	220	155	Filing a brief in support of an appeal
		121	270	221	135	Request for oral hearing
		138	1,510	138	1,510	Petition to institute a public use proceeding
		140	110	240	55	Petition to revive – unavoidable
		141	1,240	241	620	Petition to revive – unintentional
		142	1,240	242	620	Utility issue fee (or reissue)
		143	440	243	220	Design issue fee
		144	600	244	300	Plant issue fee
		122	130	122	130	Petitions to the Commissioner
		123	50	123	50	Petitions related to provisional Applications
		126	240	126	240	Submission of Information Disclosure Statement
		581	40	581	40	Recording each patent assignment per property (times number of properties)
		146	710	246	355	Filing a submission after final rejection (37 CFR 1.129(a))
		149	710	249	355	For each additional invention to be examined (37 CFR 1.129(b))
Other Fee (specify)						
Other Fee (specify)						

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

0.00

SUBMITTED BY

Complete (if Applicable)

Type or Printed Name E. Victor Donahue

Reg. Number 35,492

Signature

Date

September 27, 2001

Deposit Account

User ID

Certificate of Express Mailing under 37 CFR 1.10

The undersigned hereby certifies that the listed documents attached hereto were deposited this day with the United States Postal Service as Express Mail, Post Office to Addressee, postage prepaid, in an envelope bearing **Express Mail Label**
EL625565265US addressed to the Commissioner for Patents, Box New Application, Washington, DC 20231.

Utility Application Transmittal (in duplicate)

Fee Calculation Sheet (in duplicate)

Preliminary Amendment

Specification and claims entitled "SUBSTITUTED BICYCLIC DERIVATIVES FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS" consisting of 71 pages of text, 10 pages of claims, 1 page Abstract

09

Copy of Inventor Declaration from parent ~~9~~300,262 application

Return Receipt Postcard

Date: September 27, 2001


E. Victor Donahue